Patients Discontinuing Slimming Injections Regain Pounds Four Times Faster Compared to People Using Diet and Exercise

A recent study suggests that people who stop using blockbuster GLP-1 drugs like semaglutide or tirzepatide may regain lost weight at a significantly accelerated pace than those who stop traditional lifestyle plans.

Findings released in a prominent medical journal demonstrates that while obese individuals frequently drop a large proportion of their body weight while undergoing treatment, the mass is regained at an average rate of nearly a kilo each month upon discontinuation.

"Users using such drugs need to be cognizant of the danger of rapid rebound weight gain when the therapy ends," cautioned expert Dr. Susan Jebb.

That rate of regain implies a return to pre-treatment weight in about one and a half years.

Analyzing Therapies

The analysis, which looked at dozens of studies involving thousands of patients, contrasted the results of the injectable medications with conventional dieting.

Scientists point out that individuals who lose weight through diet and exercise usually experience a less rapid weight regain—around 100 grams monthly—once they finish.

Explaining the Rapid Rebound

Doctors suggest the mode of action of the injections explains the amplified regain.

These medications mimic a natural hormone called GLP-1, which controls appetite.

"Artificially providing GLP-1 concentrations several times higher than the body's typical production might result in the body to generate a reduced amount of its endogenous hormone, and could diminish sensitivity to its effects," explained Dr. Adam Collins, a dietetics researcher.

"Discontinuation of this hormone supplement results in hunger is uncontrolled, making excessive eating far more likely."

A Chronic Condition?

Health authorities advise the injections for individuals with obesity-related health risks, alongside prescribed diet and exercise modifications.

Professionals argue that, considering the high risk of relapse, the treatment is often life-long.

This perspective is reinforced by pharmaceutical companies, who note that the results "highlight the persistent character of obesity," akin to managing conditions like diabetes.

Patient Accounts

Users who have stopped the jabs explain a sudden resurgence of appetite.

"It was like a switch flipping and you become ravenous," said a patient.

This difficulty is worsened if patients have not developed sustainable lifestyle or habit changes during treatment.

Growing Use

Survey data show that a significant number of people in the UK have used weight-loss jabs in the past year, with demand continuing to grow.

• Adoption is more common among women than men.
• The middle-aged demographic shows the greatest level of interest.
• A large proportion obtain the drugs through private prescriptions rather than the NHS.

Ultimately, clinicians emphasize that while the jabs are potent tools for weight loss, they are not a magic solution and maintained weight loss likely depends on combined behavioural support.